8-K
filed June 1, 2023, 7:59 PM ET
CIK 0001621227
M&A
confidence high
sentiment positive
materiality 0.75
Adaptimmune Therapeutics PLC: M&A transaction — Adaptimmune completes all-stock combination with TCR2; creates solid tumor cell therapy leader
Adaptimmune Therapeutics PLC
- Merger closed June 1, 2023; Adaptimmune shareholders own ~75%, former TCR2 stockholders own ~25% of combined company.
- BLA for afami-cel (synovial sarcoma) on track for mid-2023; 70% of responders alive at 2 years in SPEARHEAD-1 trial.
- New directors appointed: Andrew Allen, Priti Hegde, Garry Menzel (ex-TCR2); Barbara Duncan and James Noble resigned.
- Combined pipeline targets MAGE-A4, mesothelin, PRAME, CD70; company funded into early 2026.
- Dr. Garry Menzel receives separation: $1.28M severance (18 months), $343,750 bonus, $171,875 transaction bonus.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Andrew R. Allen was appointed as director at Adaptimmune Therapeutics PLC.
- Action
- appointed
- Role
- director
Exact text from the filing
the Adaptimmune Board appointed Andrew R. Allen, M.D., Ph.D.; Priti Hegde, Ph.D.; and Garry E. Menzel, Ph.D., each of whom were members of the board of directors of TCR 2 , to serve as directors for a term commencing upon the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
James Noble resigned as director at Adaptimmune Therapeutics PLC.
- Action
- resigned
- Role
- director
Exact text from the filing
Barbara Duncan and James Noble resigned as directors of Adaptimmune.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Barbara Duncan resigned as director at Adaptimmune Therapeutics PLC.
- Action
- resigned
- Role
- director
Exact text from the filing
Barbara Duncan and James Noble resigned as directors of Adaptimmune.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Garry E. Menzel was appointed as director at Adaptimmune Therapeutics PLC.
- Action
- appointed
- Role
- director
Exact text from the filing
the Adaptimmune Board appointed Andrew R. Allen, M.D., Ph.D.; Priti Hegde, Ph.D.; and Garry E. Menzel, Ph.D., each of whom were members of the board of directors of TCR 2 , to serve as directors for a term commencing upon the Effective Time.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Priti Hegde was appointed as director at Adaptimmune Therapeutics PLC.
- Action
- appointed
- Role
- director
Exact text from the filing
the Adaptimmune Board appointed Andrew R. Allen, M.D., Ph.D.; Priti Hegde, Ph.D.; and Garry E. Menzel, Ph.D., each of whom were members of the board of directors of TCR 2 , to serve as directors for a term commencing upon the Effective Time.
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.95
Adaptimmune Therapeutics PLC completed an acquisition involving TCR 2 Therapeutics Inc. for all-stock transaction (closed 2023-06-01).
- Action
- acquisition
- Counterparty
- TCR 2 Therapeutics Inc.
- Consideration
- all-stock transaction
- Closing
- 2023-06-01
Exact text from the filing
On June 1, 2023, Adaptimmune Therapeutics plc, a public limited company incorporated in England and Wales (“ Adaptimmune ”), completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to the Agreement and Plan of Merger entered into as of April 5, 2023 (as amended, the " Merger Agreement "), with TCR 2 Therapeutics Inc., a Delaware corporation (" TCR 2 "), Adaptimmune, and CM Merger Sub, Inc., a Delaware corporation and an indirect wholly-owned subsidiary of Adaptimmune (" Merger Sub ").
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.